Groundbreaking Type 1 Diabetes Drug Gets NHS Green Light in England and Wales

Historic Breakthrough in Type 1 Diabetes Treatment

For the first time in more than a century, a drug capable of delaying the onset of type 1 diabetes has been approved for use on the NHS in England and Wales. The decision represents the most significant advancement in diabetes care since the discovery of insulin over 100 years ago, offering millions of people at risk a genuine chance to postpone the life-altering demands of the condition.

The immunotherapy drug teplizumab — commercially known as Tzield and manufactured by pharmaceutical giant Sanofi — does not eliminate type 1 diabetes entirely, but has been shown to delay its progression by as long as three years. The National Institute for Health and Care Excellence (NICE) formally approved the treatment, hailing it as a landmark step forward in tackling the disease.

What Is Type 1 Diabetes and Who Does It Affect?

Type 1 diabetes is a lifelong autoimmune condition that affects millions of people around the world. It most commonly develops during childhood or adolescence, arising when the body's immune system mistakenly destroys the insulin-producing cells in the pancreas. Without sufficient insulin — the hormone responsible for enabling glucose to enter cells and generate energy — the body cannot function properly.

Until now, the only available treatment has been insulin therapy, a discovery dating back 105 years. While insulin effectively manages the condition, it does not address its underlying cause or alter its progression in any way.

How Teplizumab Works

Unlike insulin, teplizumab targets the root cause of type 1 diabetes by retraining the immune system to stop its attack on the insulin-producing cells within the pancreas. The treatment is administered intravenously — delivered through a drip once daily over a 14-day course, with each session lasting approximately 30 minutes. The dosage begins at a lower level and is incrementally increased throughout the treatment period. Once the 14-day course concludes, no further treatment is required.

NICE has approved teplizumab for use in both adults and children aged eight and older who have been diagnosed with early-stage, pre-symptomatic type 1 diabetes — known medically as stage 2. By intervening at this critical window, the drug can provide eligible patients with years of relatively normal life before the full weight of diabetes management sets in.

Why This Approval Is a Game-Changer

The significance of this approval cannot be overstated. For children and teenagers in particular, the extra years gained before developing symptomatic diabetes could prove transformative — allowing them to reach crucial developmental milestones without the constant burden of monitoring blood sugar levels, administering insulin, and managing the extensive daily routine that comes with the condition.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, described the approval as the dawn of a new era. "Today's landmark approval of teplizumab marks the start of a new age of type 1 diabetes treatment," she said. "For the first time in 100 years, we are moving beyond insulin, with a medicine that targets the root cause of the condition."

She added that the development signals a hopeful shift toward a future where type 1 diabetes could ultimately be prevented altogether.

A Moment of Celebration for the Diabetes Community

Karen Addington, Chief Executive of the diabetes charity Breakthrough T1D, echoed that sentiment, calling the approval an "incredible moment" for those living with or at risk of type 1 diabetes. She emphasized the profound emotional and practical value of having more time before diagnosis — especially for families watching their children face the condition.

"If it were your child or someone you love, you would want to do everything possible to give them more years without the daily burden of managing this relentless condition," Addington said. "We now have a treatment that can help make that possible."

Accessibility and NHS Availability

Sanofi has reached a confidential commercial agreement with NHS England, meaning teplizumab will be made available at a discounted price, ensuring the drug is financially viable for the health service. Helen Knight, Director of Medicines Evaluation at NICE, confirmed that the approval was based on rigorous, evidence-driven assessment, carefully balancing clinical benefits against value for taxpayers.

"This is a genuinely exciting recommendation," Knight stated. "For the first time, we have a treatment that can give people diagnosed at an early stage of type 1 diabetes precious extra time before they need to manage the full demands of the condition."

Early Detection Is Key

Healthcare leaders are now emphasizing the importance of early screening and diagnosis to ensure as many eligible patients as possible can benefit from the treatment. Identifying type 1 diabetes before symptoms emerge is essential to unlocking the full potential of teplizumab, and efforts are already underway to ensure fair and equitable access across all communities.

This approval marks not just a medical milestone, but a moment of genuine hope — proof that after more than a century of relying solely on insulin, science is finally moving the needle on one of the world's most prevalent autoimmune conditions.